BCL2 and B-cell chronic lymphocytic leukemia: After ABT-199 was awarded as ‘Breakthrough Therapy Designation’ by the US Food and Drug Administration (FDA) in recognition of its prospects for treatment of patients with chemotherapy- resistant CLL, Bcl-2 inhibitors become a major research area.